Abstract 733P
Background
The incidence of testicular cancer (TC) has been rising over the past five decades for reasons currently unknown. As marijuana use is believed to increase the risk of TC, we sought to assess recent trends in incidence rates in California to see if further changes might be due to recent policy initiatives such as marijuana legalization.
Methods
Men diagnosed with TC between 2000 and 2020 were identified through the California Cancer Registry database (n = 23,214). Cancer occurrence by age and race/ethnicity were examined. Incidence rates by year of diagnosis and race/ethnicity were calculated, and age-adjusted to the 2000 US Standard Population.
Results
The incidence of TC among all racial/ethnic groups has been rising in California between 2000 and 2020. In particular, incidence has been rising at faster pace among Hispanic men and Asian/Pacific Islander men during this period. Among Hispanic men, the incidence rate was 4.2/100,000 in 2000 and rose to 6.7/100,000 in 2020. Similarly, the incidence rate for Asian/Pacific Islander men was 2.0/100,000 in 2000, decreased to 1.2/100,000 in 2002 and rose to 2.5/100,000 in 2020. This increasing trend for incidence rates is mainly observed among men below age 40. Table: 733P
Incidence rates for male malignant testicular cancer in California, 2000-2020
Year | All groups | Non-Hispanic white | Non-Hispanic black | Hispanic | Asian/Pacific Islander |
2000 | 5.3 | 7.3 | 1.7 | 4.2 | 2 |
2001 | 5.2 | 7.4 | 2.1 | 3.7 | 1.6 |
2002 | 5 | 7.1 | 1.5 | 3.8 | 1.2 |
2003 | 5.3 | 7.7 | 4 | 1.4 | |
2004 | 5.3 | 7.5 | 1.4 | 4.2 | 1.5 |
2005 | 5.5 | 7.8 | 1.3 | 4.3 | 2 |
2006 | 5.5 | 7.3 | 1.6 | 4.8 | 1.8 |
2007 | 5.5 | 7.5 | 1.9 | 4.6 | 2.1 |
2008 | 5.7 | 7.9 | 2.2 | 4.9 | 1.5 |
2009 | 5.6 | 7.3 | 1.9 | 5.1 | 2.2 |
2010 | 5.8 | 7.8 | 1.9 | 5.1 | 2.1 |
2011 | 5.5 | 7.3 | 1.3 | 5.3 | 2 |
2012 | 5.7 | 7.3 | 1.8 | 5.5 | 2.1 |
2013 | 6 | 8.3 | 1.8 | 5.3 | 2.4 |
2014 | 6.2 | 8 | 1.5 | 5.9 | 2.5 |
2015 | 6 | 7.2 | 1.3 | 6.3 | 2.2 |
2016 | 6.3 | 8.3 | 2 | 5.7 | 2.3 |
2017 | 6.4 | 7.7 | 1.7 | 6.6 | 2.6 |
2018 | 6.4 | 8 | 1.9 | 6.4 | 2.6 |
2019 | 6.3 | 7.3 | 1.6 | 6.8 | 2.4 |
2020 | 6.4 | 7.6 | 2 | 6.7 | 2.5 |
Rates are per 100,000 and age-adjusted to 2000 US Std Population (19 age groups – Census P25-1130) standard.
Conclusions
This is one of the largest epidemiological studies on TC. The incidence of TC has been rising in California since 2000, particularly among Hispanic and Asian/Pacific Islander men. The rise in TC rates started prior to the year of marijuana legalization (2015), thus suggesting other factors may be leading to rising incidence rates.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
A. Rezazadeh Kalebasty: Financial Interests, Personal, Stocks/Shares: ECOM Medical; Financial Interests, Personal, Advisory Role: AstraZeneca, Bayer, Bristol Myers Squibb, EMD Serono, Exelixis, Immunomedics, Genentech, Gilead Sciences, Novartis, Pfizer; Financial Interests, Personal, Speaker’s Bureau: Amgen, Astellas Medivation, AVEO, AstraZeneca, Bristol Myers Squibb, Eisai, EMD Serono, Exelixis, Genentech/Roche, Gilead Sciences, Janssen, Merck, Myocant Sciences, Novartis, Pfizer, Sanofi, Seattle Genetics; Financial Interests, Personal, Research Funding: Astellas Pharma, AstraZeneca, Bavarian Nordic, Bayer, Beyond Spring, BioClin Therapeutics, Bristol Myers Squibb, Clovis Oncology, Eisai, Epizy, Exelixis, Genentech, Immunomedics, Janssen, Macrogenics, Seattle Genetics; Financial Interests, Personal, Other: Astellas Medivation, AstraZeneca, Bayer, Eisai, Exelixis, Genentech, Janssen, Novartis, Pfizer, Prometheus Laboratories. All other authors have declared no conflicts of interest.
Resources from the same session
107P - Comprehensive genomic profiling of “The German-registry of incidental gallbladder carcinoma” cases
Presenter: Nihat Bugra Agaoglu
Session: Poster session 17
108P - FGFR2 fusions and their impact on efficacy of standard chemotherapy in patients with biliary tract cancer
Presenter: Binbin Zheng-Lin
Session: Poster session 17
109P - DNA damage repair pathways in biliary tract cancer: A new target for precision medicine?
Presenter: Ilektra Mavroeidi
Session: Poster session 17
110P - Detection of HER2 overexpression in biliary tract cancers: Comparison of AmoyDx® HER-2 (29D8) assay with ventana PATHWAY anti-HER-2/neu (4B5) assay
Presenter: Hui Dong
Session: Poster session 17
111P - The concordance between circulating tumor DNA and tissue genomic profiling in patients with advanced biliary tract cancer
Presenter: Seonjeong Woo
Session: Poster session 17
112P - Clinical, genomic and transcriptomic characteristics of young-onset biliary tract cancers
Presenter: Thomas Pudlarz
Session: Poster session 17
113P - Molecular profiling of biliary tract cancers in patients of African and European ancestries
Presenter: Zishuo Hu
Session: Poster session 17
114P - Prospective longitudinal tumor-informed ctDNA in resectable biliary tract cancers
Presenter: Gentry King
Session: Poster session 17
115P - Inhibition of KLF5 reduces tumor growth and sensitizes to chemotherapy-induced cell death in experimental models of cholangiocarcinoma
Presenter: Ana Landa Magdalena
Session: Poster session 17